Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06084780
Other study ID # CASE7Z23
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date October 2024
Est. completion date December 31, 2025

Study information

Verified date May 2024
Source Case Comprehensive Cancer Center
Contact Anil Vaidya, MD
Phone 216-445-3041
Email VAIDYAA2@ccf.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this prospective phase 2 study is to assess the efficacy and safety of intestinal or multivisceral transplantation for participants with PMP not amenable to other curative-intent treatments. Participants will undergo intestinal/multivisceral transplantation. Participants will be followed for 12 months to assess efficacy and safety.


Description:

Pseudomyxoma peritonei (PMP) is a rare clinical entity (approximately 2-4 cases per million people) characterized by extensive dissemination of mucinous ascites in the abdominal cavity. Relentless accumulation of mucin causes progressive abdominal distention, intestinal obstruction, malnutrition, cachexia, and ultimately death. As a rare disease, diagnosis is often late, and usually occurs when the disease is in a clinically advanced stage. The prognosis of PMP has been dramatically improved by the introduction of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). While outcomes are favorable for participants with disease amenable to CRS+HIPEC, the therapeutic options for participants with unresectable PMP are limited. Intestinal transplantation represents a therapeutic option in participants with unresectable PMP. Overall survival has been shown to improve with participants with unresectable PMP during an Oxford Transplant Center study. The goal of this study is to corroborate the Oxford results on an American cohort.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date December 31, 2025
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Subjects must have histologically confirmed pseudomyxoma peritonei (PMP) - Both low-grade mucinous carcinoma peritonei (LMCP) or high-grade mucinous carcinoma (HMCP), with or without signet ring cells as well as primary or recurrent disease, will be eligible. - PMP disease does not have any extra-abdominal metastases, with the exception of pulmonary involvement (nodal, parenchymal, and pleural). - PMP disease is extensive and not amenable to operative management, with or without liver, pancreas, stomach, or abdominal wall involvement. - Definition of Non-Resectable Disease- - Non-resectable PMP disease will be defined as the presence of at least one of the following conditions: - 1) Extensive small bowel serosa involvement, where it is not possible to preserve at least 1.5-2 m of small bowel - 2) Extensive infiltration of the pancreatic surface - 3) Mesenteric involvement causing retraction - 4) Need for complete gastric resection - 5) Urete1ic obstruction - 6) Liver disease with no chance to achieve R0 resection with liver remnant volume > 30% - 7) Recurrent disease not amenable to further resection - Subjects do not have any other available curative treatment options. - Subjects can have previous abdominal operations, including CRS+HIPEC. - Age = 18 and = 75. - Pediatric participants were excluded as PMP is a disease that affects adults. Participants > 75 years of age are excluded as they are beyond the commonly accepted transplantability criteria. - Performance status ECOG = 1. - Subjects must have the ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: - Subjects with peritoneal carcinomatous originating from an etiology other than PMP. - Subjects receiving any other investigational agents. - Subjects with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would either put participation at risk because of participation in the study, may influence the result of the study, or limit compliance with study requirements. - Pregnant women are excluded from this study because an intestinal transplant is a procedure that is not compatible with a viable pregnancy. - Subjects who are HIV-positive may be included in the study. HIV testing is required for the study as adequate HIV treatment is required prior to intestinal transplant due to the increased risk of infection following transplantation and treatment with immunosuppressive agents.

Study Design


Intervention

Procedure:
Intestinal, Multivisceral or Modified Multivisceral Transplantation
Enrolled participants will enter the active transplant waiting list within one month of signing informed consent for study participation. Participants can be listed for: Isolated small bowel transplant (SBT): transplantation of the donor small intestine Modified multivisceral tran I lant (MMVT): transplantation of the donor pancreas and small intestine, with or without stomach Multivisceral transplant (MVT): transplantation of the donor pancreas, small intestine, and liver, with or without stomach
Drug:
Alemtuzumab
A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Alemtuzumab as Antibody Induction Therapy. Participants will be administered two doses of Alemtuzumab (30 mg IV) on days 0 and 1.
Tacrolimus
A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Tacrolimus for maintenance. Participants will have Tacrolimus for the first 3 months. Dosing of Tacrolimus will depend on participant target level, starting with 0.05 mg/Kg bid.
Sirolimus
A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Sirolimus for maintenance. Participants will have Sirolimus after 3 months of Tacrolimus. Dosing of Sirolimus will depend on participant target level, starting with 2 mg od.

Locations

Country Name City State
United States Cleveland Clinic Digestive Disease & Surgery Institute (DDSI), Case Comprehensive Cancer Center Cleveland Ohio

Sponsors (1)

Lead Sponsor Collaborator
Case Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Rate of Survival To determine overall 12-month survival after intestinal or multivisceral transplantation in participants with unresectable PMP. 12 months post operative
Secondary Overall Rate of Morbidity Determine the morbidity of intestinal or multivisceral transplantation for participants with unresectable at 90 days by monitoring severe adverse events as classified according to Clavien-Dindo grade and comprehensive complication index. 90 days post operative
Secondary Overall Rate of Morbidity Determine the morbidity of intestinal or multivisceral transplantation for participants with unresectable at 12 months by monitoring severe adverse events as classified according to Clavien-Dindo grade and comprehensive complication index. 12 months post operative
Secondary Overall Rate of Mortality Determine cancer-related and transplant-related mortality after intestinal or multivisceral transplantation in participants with unresectable PMP. 12 months post operative
See also
  Status Clinical Trial Phase
Recruiting NCT04024917 - Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis N/A
Completed NCT02374411 - Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients N/A
Recruiting NCT02073500 - Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Active, not recruiting NCT01427101 - Results of CRS and Debulking in PMP Patients N/A
Active, not recruiting NCT04982146 - Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei Phase 1
Completed NCT04088786 - Phase I Trial HIPEC With Nal-irinotecan Phase 1
Active, not recruiting NCT02834169 - French National Registry of Rare Peritoneal Surface Malignancies N/A
Completed NCT01764789 - Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer N/A
Completed NCT02040142 - Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Phase 2
Withdrawn NCT04125225 - What Are the Experiences of Patients With Pseudomyxoma Peritonei?
Not yet recruiting NCT03976973 - BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei Phase 2
Recruiting NCT01617382 - Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed
Completed NCT01652794 - Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer Phase 1
Completed NCT01126346 - Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) N/A
Completed NCT05513183 - Severe Neutropenia After HIPEC Using Mitomycin-C
Active, not recruiting NCT02834013 - Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Phase 2
Recruiting NCT03210298 - International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
Active, not recruiting NCT02387203 - Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin Phase 2
Terminated NCT04665921 - A Study of SGN-STNV in Advanced Solid Tumors Phase 1
Recruiting NCT05321329 - Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients Phase 2